Sandra Horning

Clinical Focus

• Burkitt's Lymphoma
• Burkitt's Lymphoma - Hematology
• Burkitt's Lymphoma - Medical Oncology
• Hodgkin's Disease - Blood and Marrow Transplant
• Hodgkin's Disease - Medical Oncology

Administrative Appointments

• President, ASCO (2005 - 2006)
• President-Elect, ASCO (2004 - 2005)

Honors and Awards

• Alwin C. Rambar-James B. D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2000)

Professional Education

Postdoctoral Advisees

ChunFang Zhu

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

The objectives of the clinical research program are:
1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkin’s disease (HD) and the non-Hodgkin’s lymphomas (NHL).

The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.

Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials. Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations

Clinical Trials

• A Phase I Dose Escalation Study of Weekly SGN-35 Alone and in Combination With Gemcitabine in HL Recruiting
• A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma Recruiting
• Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Recruiting
• Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Recruiting
• Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT) Recruiting

Publications

• Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Weinberg OK, Ma L, Seo K, Beck AH, Pai RK, Morales A, Kim Y, Sundram U, Tan D, Horning SJ, Hoppe RT, Natkunam Y, Arber DA. Am J Surg Pathol. 2009; 33 (4): 591-8
• Interim positron emission tomography (PET) scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Horning SJ, Juweid ME, Schoder H, Wiseman G, McMillan A, Swinnen LJ, Advani R, Gascoyne R, Quon A. Blood. 2009
• Cancer research and privacy: the problem with being joined at the hip. Horning SJ, J Clin Oncol. 2009; 27 (24): 3879-80
• Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. J Clin Oncol. 2009; 27 (10): 1607-14
• (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Iagaru A, Wang Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS. Hell J Nucl Med. 2008 Sep-Dec; 11 (3): 153-6